Previous 10 | Next 10 |
2023-04-24 17:38:49 ET Summary Shares have lost a third of their value over the past year. HSC-based gene therapy Libmeldy is approved in the EU for MLD with a ~$3.5M price tag. Incidence could be higher than initial estimates. Cash position was bolstered with March financing,...
BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the Guggenheim Genomic Medicines and Rare Disease Day on Tuesday, April 4, 2023 at 1:35pm ET. A live ...
2023-03-28 14:57:47 ET The following slide deck was published by Orchard Therapeutics plc in conjunction with this event. For further details see: Orchard Therapeutics (ORTX) Investor Presentation - Slideshow'
2023-03-10 15:17:07 ET Orchard Therapeutics plc (ORTX) Q4 2022 Earnings Conference Call March 06, 2023 8:00 AM ET Company Participants Bobby Gaspar - Chief Executive Officer Frank Thomas - President and COO Braden Parker - Chief Commercial Officer Leslie Melt...
BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Company’s previously disclosed change to its American Depositary Share ("ADS") to ordinary share ratio has been made effective. The ratio ha...
2023-03-06 06:28:59 ET Orchard Therapeutics press release ( NASDAQ: ORTX ): Q4 GAAP EPS of -$0.06 beats by $0.15 . Revenue of $6.97M beats by $1.66M . Cash, cash equivalents and investments as of December 31, 2022, were $143.8 million, with $32.4 million of deb...
2023-03-06 06:16:15 ET Orchard Therapeutics ( NASDAQ: ORTX ) announced up to $188M in strategic financing to drive the commercialization of its gene therapy product, Libmeldy. The firm entered into a securities purchase agreement for the sale of ordinary shares and warrants ...
OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare investors provides up to $188 million of additional capital upon achievement of key milest...
Proceeds to accelerate commercialization of Libmeldy and advance the company’s HSC gene therapy R&D portfolio Initial closing of $34 million to support execution and extend cash runway into 2025 with potential for significant additional capital at increasing valuations ...
BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences: TD Cowen 43 rd Annual Healthcare Conference on March 7, 2023...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....